Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307268 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Alvin Shrestha und 35 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Respiratory Interface Section, National Heart and Lung Institute, Imperial College London, South Kensington Campus, London, United…. Hauptthemen laut MEDLINE: Receptor, Bradykinin B2, Sarcopenia, Physical Functional Performance. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Efficacy and Mechanism Evaluation (EME) Programme, NIHR Newcastle Biomedical Research Centre, Health Services Research Unit.
Abstract (Originalsprache)
Introduction
Understanding genetic contributors to sarcopenia (age-related loss of muscle strength and mass) is key to finding effective therapies. Variants of the bradykinin receptor 2 (BDKRB2) have been linked to athletic and muscle performance. The rs1799722–9 and rs5810761 T alleles have been shown to be overrepresented in endurance athletes, possibly due to increased transcriptional rates of the receptor. These variants have been rarely studied in older people or people with sarcopenia.
Methods
We performed a post hoc sub-study of the Leucine and ACE (LACE) inhibitor trial, which enrolled 145 participants aged ≥70 years with low grip strength and low gait speed. Participants’ blood samples were genotyped for rs179972 using TaqMan and rs5810761 by amplification through Hotstar Taq. Genotypes were compared with outcomes of physical performance and body composition measures.
Results
Data from 136 individuals were included in the analysis. For rs1799722 the genotype frequency (TT: 17, CC: 48, CT: 71) remained in Hardy-Weinberg Equilibrium (HWE p = 0.248). There was no difference between the genotypes for six-Minute Walk Distance (6MWD) or Short Physical Performance Battery (SPPB). Men with the TT genotype had a significantly greater 6MWD than other genotypes (TT 400m vs CT 310m vs CC 314m, p = 0.027), and greater leg muscle mass (TT 17.59kg vs CT 15.04kg vs CC 15.65kg, p = 0.007). For rs5810761, the genotype frequency (-9-9: 31, +9+9: 43, -9+9: 60) remained in HWE (p = 0.269). The +9+9 genotype was associated with a significant change in SPPB score at 12 months (-9-9 0 vs -9+9 0 vs +9+9–1, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cardiovascular and Respiratory Interface Section, National Heart and Lung Institute, Imperial College London, South Kensington Campus, London, United Kingdom.
- Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, United Kingdom.
- Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
- Liverpool University Hospitals NHS FT Trust, Clinical Research Network Northwest Coast, University of Liverpool, Liverpool, United Kingdom.
- AGE Research Group, NIHR Newcastle Biomedical Research Centre, Cumbria Northumberland Tyne and Wear NHS Foundation Trust and Newcastle upon Tyne Hospitals NHS Trust, Translational Clinical Research Institute, Newcastle…
- Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom.
ORCID-Profile: Alvin Shrestha, Harnish Patel, Kristina Pilvinyte, Roy L Soiza
Förderung
- Efficacy and Mechanism Evaluation (EME) Programme
- NIHR Newcastle Biomedical Research Centre
- Health Services Research Unit
Zitieren
APA
Shrestha, A., Bashir, T., Achison, M., Adamson, S., Akpan, A., Aspray, T., Avenell, A., Band, M. M., Burton, L. A., Cvoro, V., Donnan, P. T., Duncan, G. W., George, J., Gordon, A. L., Gregson, C. L., Hapca, A., Hume, C., Jackson, T. A., Kerr, S., …, & Kemp, P. R. (2024). Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0307268
Vancouver
Shrestha A, Bashir T, Achison M, Adamson S, Akpan A, Aspray T, et al. Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0307268
BibTeX
@article{Shrestha2024,
author = {Shrestha, Alvin and Bashir, Tufail and Achison, Marcus and Adamson, Simon and Akpan, Asangaedem and Aspray, Terry and Avenell, Alison and Band, Margaret M and Burton, Louise A and Cvoro, Vera and Donnan, Peter T and Duncan, Gordon W and George, Jacob and Gordon, Adam L and Gregson, Celia L and Hapca, Adrian and Hume, Cheryl and Jackson, Thomas A and Kerr, Simon and Kilgour, Alixe and Masud, Tahir and McKenzie, Andrew and McKenzie, Emma and Patel, Harnish and Pilvinyte, Kristina and Roberts, Helen C and Sayer, Avan A and Rossios, Christos and Smith, Karen T and Soiza, Roy L and Steves, Claire J and Struthers, Allan D and Tiwari, Divya and Whitney, Julie and Witham, Miles D and Kemp, Paul R},
title = {Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307268}
}
EUVIMED